ERG and prostate cancer: To explain the observed co-expression, we employed cellular models of prostate cancer, including cells representing benign (RWPE-1, BPH-1), fusion-negative (PC-3, DU145), ERG-rearranged (VCaP, NCI-H660) and ETV1-rearranged (LNCaP) prostate cancer.